Robert C. Shepard

i3 Research, Inc. undertakes medical research services. The company focuses on central nervous system, oncology, respiratory and infectious diseases, endocrinology and metabolic diseases, and cardiology. It offers clinical research solutions, including project management, investigator recruitment, patient recruitment, and regulatory services. The company is located in Basking Ridge, NJ.

Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN.

Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY.

i3 Global operates as a pharmaceutical services company. It offers therapeutically specialized contract research solutions, clinical data services, staffing solutions, pharmacovigilance and epidemiology solutions. The company was founded in 1988 and is headquartered in Bernards, NJ.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Accevolance, Inc. engages in providing clinical research and development services. It operates through the following core service divisions: Full-Service CRO, Patient Recruitment, and Clinical Call Center. The Full-Service CRO division includes protocol development, project management, clinical trial monitoring, data management, Biostatistics, Pharmacovigilance, regulatory affairs, and medical writing. The Patient Recruitment division involves patient recruitment and management. The Clinical Call Center division provides recruitment, retention, and compliance; post approval safety studies; Phase IV studies; surveillance programs; patient-reported outcomes; observational studies; registries; site support services; patient market research; and risk management support. The company was founded by Stephen J. Trevisan in 2005 and is headquartered in Rockville, MD.

PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ.